Skip Navigation
Skip to contents

KMJ : Kosin Medical Journal

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > Kosin Med J > Volume 40(3); 2025 > Article
Case report
A healthy female adolescent with idiopathic scoliosis who presented with recurrent dyspnea and wheezing: a case report
Jin Ku Kimorcid, Yoon Ha Hwangorcid
Kosin Medical Journal 2025;40(3):221-226.
DOI: https://doi.org/10.7180/kmj.25.112
Published online: September 25, 2025

Department of Pediatrics, Busan St. Mary's Medical Center, Busan, Korea

Corresponding Author: Yoon Ha Hwang, MD, PhD Department of Pediatrics, Busan St. Mary's Medical Center, 25-14 Yongho-ro 232beon-gil, Nam-gu, Busan 48575, Korea Tel: +82-51-933-7988 Fax: +82-51-932-8622 E-mail: hyh190@naver.com
• Received: April 25, 2025   • Revised: July 21, 2025   • Accepted: August 22, 2025

© 2025 Kosin University College of Medicine.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 849 Views
  • 15 Download
prev next
  • A 15-year-old female adolescent visited our hospital’s outpatient and emergency departments several times due to recurrent paroxysmal dyspnea for 6 months. Based on the clinical symptoms, the researchers empirically diagnosed bronchial asthma and treated the patient with oral steroids and inhaled corticosteroid agents; however, her symptoms did not significantly improve. As part of the differential diagnosis, thoracic scoliosis was observed in previous chest X-ray images. The patient’s records from 2018 (patient age, 10 years) and 2023 (patient age, 15 years) showed that scoliosis had progressed during her rapid growth period). As the symptoms did not improve despite ongoing medication, further evaluation was performed. Contrast-enhanced chest computed tomography revealed a thoracic eighth vertebral body compressing the right bronchus intermedius. The patient rarely wore the existing brace due to discomfort, but a new custom brace was prescribed based on chest computed tomography findings. Since then, the patient’s compliance with treatment increased and she gradually increased the amount of time she wears the brace. In addition, her Cobb’s angle and pulmonary function tests improved in outpatient follow-up visits. The patient’s recurrent dyspnea and wheezing were originally considered to be an asthma exacerbation, prompting treatment with medication, but the symptoms did not improve. Therefore, clinicians should be careful to keep in mind the possibility of other diseases in patients who visit the hospital with typical asthma symptoms, such as dyspnea or wheezing—especially growing adolescents—in order to avoid delaying diagnosis or treatment.
Scoliosis is caused by a three-dimensional rotational deformity of the spine [1], and can lead to various forms of respiratory disease and decreased lung function. Idiopathic scoliosis accounts for more than 85% of cases [2], and although the exact etiology is not known, it is presumed that multiple factors may be involved, such as genetic effects, congenital structural abnormalities, neuromuscular diseases, hormonal imbalance, and asymmetric growth. Severe scoliosis requiring surgical treatment defined as a Cobb’s angle greater than 45° or more [3]. In general, restrictive lung diseases are pulmonary disorders characterized by a reduced distensibility of the lungs, compromising lung expansion, and reduced lung volumes [4]. However, it can also occur in the form of obstructive lung disease, where the inner diameter of the bronchi is narrowed due to compression. Unlike this, bronchial asthma is a chronic inflammatory airway disease characterized by airway hyperresponsiveness and reversible airway obstruction [5]. This case is a study of a patient who presented with an exacerbation of asthma that did not respond to medication but improved after wearing a brace.
Ethical statements: This study was exempted from review by the Institutional Review Board (IRB) of Busan St. Mary’s Hospital (IRB No: 24-14000-134). Written informed consent was obtained from both the patient and the legal guardian after a thorough explanation of the study.
A 15-year-old female visited our hospital’s outpatient and emergency department several times due to recurrent paroxysmal dyspnea for 6 months. This patient was a healthy adolescent who had a normal vaginal delivery at 38+1 weeks, weighing 3.20 kg, and had no underlying diseases or medical history other than a thyroid nodule discovered incidentally in May 2022. She also had no history or family history of allergic diseases. On initial examination, diffuse polyphonic wheezing auscultated over both lung fields, and decreased aeration was also noted. At the time of dyspnea, tachypnea was accompanied, but oxygen administration was not required, and there were no restrictions on daily life, but shortness of breath occurred during exercise. For the results of the pulmonary function tests, refer to Table 1 (conducted on April 8, 2023).
But a chest X-ray (CXR) shows no increased opacities or consolidation/hyperinflation. Based on the clinical symptoms, the researchers empirically diagnosed bronchial asthma in December 2022 and treated the patient with short-acing beta agonist, short-acting muscarinic antagonist, leukotriene receptor antagonist, oral steroids and inhaled corticosteroid agents (Table 2) for about 6 months, however she did not show significant improvement in her symptoms. The patient visited the emergency room 3 times at night, was hospitalized 3 times, and received outpatient treatment several times for acute dyspnea over a period of approximately 6 months since December 2022. Eosinophil, serum immunoglobulin E, hemoglobin, O2 saturation, ImmunoCAP (inhalant), gas analysis values (Tables 3, 4), and transthoracic echocardiogram results were normal at presentation.
While continuing outpatient treatment, we recognized that the Cobb’s angle on CXR corresponds to 70°. Previous records showed that the scoliosis progressed during the rapid growth period in 2018 (patient age 10 years, 24.1°; Fig. 1A), 2019 (patient age 11 years, 48.3°; Fig. 1B), 2021 (patient age 13 years, 56.6°), and 2023 (patient age 15 years, 70.0°; Fig. 1C, 1D). Despite abouth 6 months of drug treatment, the symptoms did not improve much, a contrast-enhanced chest computed tomography (CT) was performed, which revealed a thoracic 8 vertebral body compressing the right bronchus intermedius and increased shading of the right middle lobe/right lower lobe (Fig. 2). There were no specific findings in the lung parenchyma on the chest CT. Follow-up chest CT scan was not performed because the patient refused it.
The patient originally had a prescribed brace, but rarely used it due to the discomfort of wearing it for a long time. However, after the cause of bronchial compression was identified through a chest CT scan, the patient’s compliance with treatment increased, and the wearing time gradually increased with a new and more comfortable scoliosis brace. In the meantime, the number of visits to the emergency room visits and hospitalizations decreased significantly, and the Cobb’s angle has decreased from 70.0° to 60.2° at outpatient follow-up, and her forced expiratory volume in 1 second (FEV1) on pulmonary function tests (PFTs) has increased from 35% to 49% (Fig. 1C, 1D, Table 1), and she has no significant limitations in her daily life.
In this case, the physicians considered the patient’s recurrent dyspnea and wheezing to be an asthma exacerbation and treated her with medication, but the symptoms did not improve. Therefore, when a patient does not respond well to asthma medications, the possibility of dyspnea or wheezing due to causes other than asthma should not be ruled out. Evaluation for scoliosis should also not be neglected, especially in growing adolescents.
This patient was a healthy middle school student with height 155 cm, weight 40 kg, body mass index 16.65 (5th percentile, underweight), who had never been hospitalized for pneumonia except during childhood, and had no history of respiratory problems such as interstitial lung disease. There is no evidence of nutritional imbalance and secondary sexual characteristics have developed normally. Additionally, there is no past medical history or family history suggestive of ankylosing spondylitis, multiple sclerosis, myasthenia gravis, etc.
Over the past few years, as the COVID-19 pandemic has passed, obesity in children and adolescents has increased due to restrictions on outdoor activities [6], and several studies have shown the relationship between obesity and scoliosis [7] and the relationship between reduced activity and scoliosis [8]. Therefore, when scoliosis is suspected during pediatric treatment, it can be said that screening roles such as standing spine X-ray examination or consultation with other departments are important.
Treatment of scoliosis includes observation, non-surgical treatment, spinal braces, surgical correction and stent treatment depending on the degree of curvature. Non-surgical treatments include physical therapy, superficial electrical stimulation, and chiropractic, but evidence on treatment effectiveness is still lacking [9]. Braces have an initial corrective effect, but since the recommended daily wear time is more than 18–20 hours [9], it is realistically difficult for patients to combine group living and treatment. In fact, a study that followed up on the effect of brace treatment for 8 months showed that the permanent improvement in lung function was limited [10]. Surgery is recommended when the curve of more than 45° is expected to progress further as it grows, or when pain persists even after growth is complete. However, even if the curvature is more than 50°, there is controversy about the necessity of surgery if the patient has completed growth or has no accompanying symptoms [9]. The biggest complication of surgery is infection [9]. According to another study, there was a case where pulmonary function temporarily improved after surgical treatment of scoliosis, but the long-term effect was still questionable [10]. There was also a case report in which pulmonary function was completely restored through stent insertion using a bronchoscope [11].
In this case, brace treatment was selected, and after 4 months, FEV1 and forced vital capacity (FVC) increased on PFTs, but FEV1/FVC ratio decreased. In other words, the increase in FVC was greater than FEV1, which can be interpreted that brace treatment was more effective for restrictive lung disease. The main opinion in the academic world is that there is little therapeutic benefit from braces at the age when growth is generally completed [1]. However, the decline in respiratory ability is not simply related to the angle of scoliosis, but is affected by a number of factors. Therefore, as in this case, clinical symptoms may show improvement, so brace treatment for scoliosis may be considered.
This patient’s symptoms improved somewhat with medications, but the pattern of relapse when medications were discontinued was repeated. However, the number of outpatient and emergency room visits due to acute dyspnea decreased rapidly with the use of new brace from June 2023. The patient’s last emergency room visit was on April 5, 2023, and the symptoms could be controlled through outpatient follow-up observations. The Cobb’s angle on CXR also began to improve (Fig. 1C, 1D). This is presumed to be because the Cobb’s angle decreased by the scoliosis brace, thereby relieving the pressure on the right bronchus intermedius.
Most cases of scoliosis show aspects of obstructive pulmonary disease caused by structural pressure, but cases showing acute worsening of asthma like this case are not common. Based on various test results, this patient is thought to be a case with a combination of both obstructive and restrictive pulmonary disease, and it was confirmed that the symptoms actually improved with both brace and drug treatment.
In the case of the patient, the methacholine challenge test was not performed because baseline FEV1 value was less than 60% of the predicted value, as it was contraindicated according to the Ministry of Food and Drug Safety guidelines (2020).

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Funding

None.

Author contributions

Conceptualization: JKK, YHH. Data curation: JKK. Investigation: JKK. Methodology: JKK, YHH. Project administration: JKK. Resources: JKK, YHH. Supervision: YHH. Visualization: JKK. Writing-original draft: JKK. Writing-review & editing: JKK, YHH. All authors read and approved the final manuscript.

Fig. 1.
Cobb’s angle on chest X-ray. (A) At the patient’s age of 10 years (24.1°). (B) At the patient’s age of 11 years (48.3°). (C) At the patient’s age of 15 years (70.0°). (D) At the patient’s age of 15 years (60.2°).
kmj-25-112f1.jpg
Fig. 2.
Compression of the right bronchus intermedius by 8th thoracic vertebra confirmed on contrast-enhanced chest computed tomography. (A) Horizontal plane. (B) Coronal plane.
kmj-25-112f2.jpg
Table 1.
Results of pulmonary function tests
Spirometry Measurement Reference Predicted value (%)
2023-04-08 2023-08-02 2023-04-08 2023-08-02 2023-04-08 2023-08-02
FVC (L) 1.23 2.12 2.99 3.08 41.1 68.8
FEV1 (L) 1.00 1.44 2.84 2.93 35.2 49.1
FEV1/FVC (%) 81.3 67.9 86.0 86.0
FEF25%–75% (L/s) 0.96 1.18 3.22 3.36 30 35

FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; FEF25%–75%, forced mid-expiratory flow 25%–75%.

Table 2.
Asthma medications used in treatment since December 2022
Medication Manufacturer Dosage
Flixotide Junior Evohaler GlaxoSmithKline 50 μg: 120 doses/bottle
Ventolin Nebule GlaxoSmithKline 2.5 mg/2.5 mL: each
Pulmicort Respule (micronized) AstraZeneca 0.5 mg: 2 mL/bottle
Solondo Tab. Yuhan Corp. 5 mg: tablet
Ventolin Evohaler GlaxoSmithKline 0.1 mg: 200 doses/bottle
Singulair Tab. Organon Canada Inc. 10 mg: tablet
Spiriva Cap. Boehringer-Ingelheim 18 μg: 30 capsules/box
Symbicort Turbuhaler AstraZeneca 320/9 μg: 60 doses/bottle
Table 3.
Results of laboratory blood tests
Variable Reference range 2022-12-27 2023-04-09
WBC differential count
 Eosinophil (%) 0–4 1.3 1.2
 IgE, total (IU/mL) 0–199.9 78.6 50.2
 Hemoglobin (g/dL) 12–17 14.7 15.6
 O2 saturation (%) 95 98
Unicap Profile 10 (inhalant, KUA/L)
 Allergen-specific IgE, T3 (birch) 0–0.35 0 (0.01)
 Allergen-specific IgE, W22 (Japanese hop) 0–0.35 0 (0.00)
 Allergen-specific IgE, W1 (common ragweed) 0–0.35 0 (0.01)
 Allergen-specific IgE, T7 (oak) 0–0.35 0 (0.03)
 Allergen-specific IgE, D1 (Dermatophagoides pteronyssinus) 0–0.35 0 (0.02)
 Allergen-specific IgE, D2 (Dermatophagoides farinae) 0–0.35 0 (0.01)
 Allergen-specific IgE, M6 (Alternaria tenuis) 0–0.35 0 (0.03)
 Allergen-specific IgE, T2 (gray alder) 0–0.35 0 (0.01)
 Allergen-specific IgE, E1 (cat) 0–0.35 0 (0.00)
 Allergen-specific IgE, E5 (dog) 0–0.35 0 (0.01)

Values in parentheses indicate actual measured values; all within negative range.

WBC, white blood cell; IgE, immunoglobulin E.

Table 4.
Results of gas analysis
Variable 2022-12-04
VBGA
 Blood pH 7.34
 pCO2 (mmHg) 58
 pO2 (mmHg) 16
 HCO3- (mmol/L) 31.3
 Total CO2 (%) 33.1
 Base excess (mmol/L) 3.7
 O2 content (mL/dL) 2.7
 O2 saturation (%) 12.1
ABGA
 Hematocrit (%) 47

VBGA, venous blood gas analysis; pCO2, partial pressure of CO2; pO2, partial pressure of O2; ABGA, arterial blood gas analysis.

  • 1. Korean Orthopaedic Association. Essential Orthopaedics. 2nd ed. Choesinuihagsa; 2004.
  • 2. Tsiligiannis T, Grivas T. Pulmonary function in children with idiopathic scoliosis. Scoliosis 2012;7:7.ArticlePubMedPMCPDF
  • 3. Altaf F, Gibson A, Dannawi Z, Noordeen H. Adolescent idiopathic scoliosis. BMJ 2013;346:f2508.ArticlePubMed
  • 4. Martinez-Pitre PJ, Sabbula BR, Cascella M. Restrictive lung disease [Internet]. StatPearls Publishing; 2025 [cited 2025 Sep 08]. Available from: https://pubmed.ncbi.nlm.nih.gov/32809715/
  • 5. Ukena D, Fishman L, Niebling WB. Bronchial asthma: diagnosis and long-term treatment in adults. Dtsch Arztebl Int 2008;105:385–94.ArticlePubMedPMC
  • 6. Stavridou A, Kapsali E, Panagouli E, Thirios A, Polychronis K, Bacopoulou F, et al. Obesity in children and adolescents during COVID-19 pandemic. Children (Basel) 2021;8:135.ArticlePubMedPMC
  • 7. Goodbody CM, Sankar WN, Flynn JM. Presentation of adolescent idiopathic scoliosis: the bigger the kid, the bigger the curve. J Pediatr Orthop 2017;37:41–6.ArticlePubMed
  • 8. Amaricai E, Suciu O, Onofrei RR, Miclaus RS, Iacob RE, Catan L, et al. Respiratory function, functional capacity, and physical activity behaviours in children and adolescents with scoliosis. J Int Med Res 2020;48:300060519895093.ArticlePubMedPMC
  • 9. Hresko MT. Clinical practice: idiopathic scoliosis in adolescents. N Engl J Med 2013;368:834–41.ArticlePubMed
  • 10. Yurt Y, Yatar I, Malkoc M, Yakut Y, Mihcioglu S, Koltak C. The effect of brace treatment on pulmonary functions in adolescent idiopathic scoliosis: an 8-month follow-up study. J Back Musculoskelet Rehabil 2021;34:887–93.ArticlePubMed
  • 11. Qiabi M, Chagnon K, Beaupre A, Hercun J, Rakovich G. Scoliosis and bronchial obstruction. Can Respir J 2015;22:206–8.ArticlePubMedPMCPDF

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      • PubReader PubReader
      • ePub LinkePub Link
      • Cite
        CITE
        export Copy
        Close
      • Download Citation
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        A healthy female adolescent with idiopathic scoliosis who presented with recurrent dyspnea and wheezing: a case report
        Kosin Med J. 2025;40(3):221-226.   Published online September 25, 2025
        Close
      • XML DownloadXML Download
      Figure
      • 0
      • 1
      A healthy female adolescent with idiopathic scoliosis who presented with recurrent dyspnea and wheezing: a case report
      Image Image
      Fig. 1. Cobb’s angle on chest X-ray. (A) At the patient’s age of 10 years (24.1°). (B) At the patient’s age of 11 years (48.3°). (C) At the patient’s age of 15 years (70.0°). (D) At the patient’s age of 15 years (60.2°).
      Fig. 2. Compression of the right bronchus intermedius by 8th thoracic vertebra confirmed on contrast-enhanced chest computed tomography. (A) Horizontal plane. (B) Coronal plane.
      A healthy female adolescent with idiopathic scoliosis who presented with recurrent dyspnea and wheezing: a case report
      Spirometry Measurement Reference Predicted value (%)
      2023-04-08 2023-08-02 2023-04-08 2023-08-02 2023-04-08 2023-08-02
      FVC (L) 1.23 2.12 2.99 3.08 41.1 68.8
      FEV1 (L) 1.00 1.44 2.84 2.93 35.2 49.1
      FEV1/FVC (%) 81.3 67.9 86.0 86.0
      FEF25%–75% (L/s) 0.96 1.18 3.22 3.36 30 35
      Medication Manufacturer Dosage
      Flixotide Junior Evohaler GlaxoSmithKline 50 μg: 120 doses/bottle
      Ventolin Nebule GlaxoSmithKline 2.5 mg/2.5 mL: each
      Pulmicort Respule (micronized) AstraZeneca 0.5 mg: 2 mL/bottle
      Solondo Tab. Yuhan Corp. 5 mg: tablet
      Ventolin Evohaler GlaxoSmithKline 0.1 mg: 200 doses/bottle
      Singulair Tab. Organon Canada Inc. 10 mg: tablet
      Spiriva Cap. Boehringer-Ingelheim 18 μg: 30 capsules/box
      Symbicort Turbuhaler AstraZeneca 320/9 μg: 60 doses/bottle
      Variable Reference range 2022-12-27 2023-04-09
      WBC differential count
       Eosinophil (%) 0–4 1.3 1.2
       IgE, total (IU/mL) 0–199.9 78.6 50.2
       Hemoglobin (g/dL) 12–17 14.7 15.6
       O2 saturation (%) 95 98
      Unicap Profile 10 (inhalant, KUA/L)
       Allergen-specific IgE, T3 (birch) 0–0.35 0 (0.01)
       Allergen-specific IgE, W22 (Japanese hop) 0–0.35 0 (0.00)
       Allergen-specific IgE, W1 (common ragweed) 0–0.35 0 (0.01)
       Allergen-specific IgE, T7 (oak) 0–0.35 0 (0.03)
       Allergen-specific IgE, D1 (Dermatophagoides pteronyssinus) 0–0.35 0 (0.02)
       Allergen-specific IgE, D2 (Dermatophagoides farinae) 0–0.35 0 (0.01)
       Allergen-specific IgE, M6 (Alternaria tenuis) 0–0.35 0 (0.03)
       Allergen-specific IgE, T2 (gray alder) 0–0.35 0 (0.01)
       Allergen-specific IgE, E1 (cat) 0–0.35 0 (0.00)
       Allergen-specific IgE, E5 (dog) 0–0.35 0 (0.01)
      Variable 2022-12-04
      VBGA
       Blood pH 7.34
       pCO2 (mmHg) 58
       pO2 (mmHg) 16
       HCO3- (mmol/L) 31.3
       Total CO2 (%) 33.1
       Base excess (mmol/L) 3.7
       O2 content (mL/dL) 2.7
       O2 saturation (%) 12.1
      ABGA
       Hematocrit (%) 47
      Table 1. Results of pulmonary function tests

      FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; FEF25%–75%, forced mid-expiratory flow 25%–75%.

      Table 2. Asthma medications used in treatment since December 2022

      Table 3. Results of laboratory blood tests

      Values in parentheses indicate actual measured values; all within negative range.

      WBC, white blood cell; IgE, immunoglobulin E.

      Table 4. Results of gas analysis

      VBGA, venous blood gas analysis; pCO2, partial pressure of CO2; pO2, partial pressure of O2; ABGA, arterial blood gas analysis.


      KMJ : Kosin Medical Journal
      TOP